This has significant therapeutic implications: small tyrosine kinase inhibitors gefitinib and erlotinib are clinically effective for the treatment of NSCLC harboring activating EGFR mutations [14, 15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.